2024
County-level racial disparities in prostate cancer specific mortality from 2005 to 2020
Washington S, Fakunle M, Wang L, Braun A, Leapman M, Cowan J, Cooperberg M. County-level racial disparities in prostate cancer specific mortality from 2005 to 2020. JNCI Cancer Spectrum 2024, pkae109. PMID: 39495143, DOI: 10.1093/jncics/pkae109.Peer-Reviewed Original ResearchNon-Hispanic blacksRacial disparitiesCancer-specific mortalityCancer outcomesAssociated with lower mortality riskProstate cancer-specific mortalityProstate cancer outcomesNon-Hispanic white patientsLinear mixed models evaluated associationsPrimary care providersSpecific mortalityRadiation oncologist densityLower mortality riskYear of deathBlack-white differencesRace-based disparitiesMortality disparitiesProvider densityCare providersCounty-level dataHospital bedsMortality riskData of menProstate cancer specific mortality riskWhite patientsFeasibility of Pay for Performance and Transparency Interventions on the Selection and Quality of Observational Management for Patients with Low-Risk Prostate Cancer in the Community Practice.
Gaylis F, Leapman M, Ellis S, Hu S, Cooperberg M, Loeb S, Chen R, Cohen E, Dato P, Aynehchi S, David R, Topp R, Santomauro B, Ginsburg K, Catalona W. Feasibility of Pay for Performance and Transparency Interventions on the Selection and Quality of Observational Management for Patients with Low-Risk Prostate Cancer in the Community Practice. Urology Practice 2024, 101097upj0000000000000745. PMID: 39453985, DOI: 10.1097/upj.0000000000000745.Peer-Reviewed Original ResearchInter-reader reliability and diagnostic accuracy of PI-RADS scoring between academic and community care networks: How wide is the gap?
Smani S, Jalfon M, Sundaresan V, Lokeshwar S, Nguyen J, Halstuch D, Khajir G, Cavallo J, Sprenkle P, Leapman M, Kim I. Inter-reader reliability and diagnostic accuracy of PI-RADS scoring between academic and community care networks: How wide is the gap? Urologic Oncology Seminars And Original Investigations 2024 PMID: 39438211, DOI: 10.1016/j.urolonc.2024.10.002.Peer-Reviewed Original ResearchClinically significant PCaPI-RADS scoreDetect clinically significant PCaReporting of prostate cancerInter-reader reliabilityProstate cancerPI-RADSDiagnostic accuracyReceiver operating characteristicInter-readerPresence of clinically significant PCaProstate Imaging Reporting & Data SystemDetect clinically significant diseasePI-RADS 3 lesionsTertiary academic care centerMRI fusion biopsyPI-RADS 3Significant PCaProstate cancer managementClinically significant diseaseInter-reader agreementSubgroup of lesionsAcademic care centerIntraclass correlationMpMRI interpretationMolecular Correlates of Prostate Cancer Visibility on Multiparametric Magnetic Resonance Imaging: A Systematic Review
Fazekas T, Pallauf M, Kufel J, Miszczyk M, Tsuboi I, Matsukawa A, Laukhtina E, Kardoust Parizi M, Mancon S, Cadenar A, Schulz R, Yanagisawa T, Baboudjian M, Szarvas T, Gandaglia G, Tilki D, Nyirády P, Rajwa P, Leapman M, Shariat S. Molecular Correlates of Prostate Cancer Visibility on Multiparametric Magnetic Resonance Imaging: A Systematic Review. European Urology Oncology 2024 PMID: 39414421, DOI: 10.1016/j.euo.2024.09.017.Peer-Reviewed Original ResearchProstate Imaging ReportingProstate cancerMagnetic resonance imagingMRI-invisible lesionsPI-RADSMRI visibilityImaging ReportingAssociated with oncologic outcomesBiologically aggressive prostate cancerHighest Prostate Imaging ReportingMultiparametric magnetic resonance imagingProstate magnetic resonance imagingPI-RADS 4PI-RADS scoreResonance imagingData System scoreAggressive prostate cancerStage prostate cancerMolecular correlatesClinically aggressive cancerPrognostic gene panelsSystematic biopsyAssociated with featuresOncological outcomesSystemic biopsyLong-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer
Kunst N, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Rabil M, Ghaffar U, Karnes R, Ma X, Gross C, Wang S, Leapman M. Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer. JAMA Network Open 2024, 7: e2440591. PMID: 39441595, DOI: 10.1001/jamanetworkopen.2024.40591.Peer-Reviewed Original ResearchConceptsProstate-specific antigenProstate-specific antigen levelPSMA-PETRecurrent prostate cancerBiochemical recurrenceProstate cancerLong-term outcomesProstate-specific membrane antigen positron emission tomographyEvaluation of biochemical recurrenceDetection of biochemical recurrenceLife yearsConventional imagingDefinitive local therapyPSMA PET imagingProstate cancer deathDetection of metastasesRetrospective cohort studyBase case analysisIncremental life-yearsPositron emission tomographyDecision-analytic modelLocal therapyConventional imaging strategiesDelayed treatmentDisease courseSociodemographic disparities in prostate cancer imaging
Sundaresan V, Lokeshwar S, Sutherland R, Sohoni N, Golos A, Ajjawi I, Leapman M. Sociodemographic disparities in prostate cancer imaging. Abdominal Radiology 2024, 1-9. PMID: 39325212, DOI: 10.1007/s00261-024-04603-2.Peer-Reviewed Original ResearchProstate cancer imagingProstate cancerProstate cancer diagnosisMonitoring of prostate cancerProstate multiparametric MRISociodemographic disparitiesProstate cancer treatmentEquitable cancer careBiochemical recurrenceFactors associated with disparitiesMultiparametric MRIActive surveillanceTreatment planningBlack patientsCancer outcomesTreatment workflowDiagnostic imagingCancer careDiagnosisRural settingsProstateImaging utilizationTreatmentPatientsCancer imagingDiagnostic utility of prostate health index density prior to MRI-ultrasound fusion targeted biopsy
Press B, Lokeshwar S, Webb L, Khajir G, Smani S, Olawoyin O, Gardezi M, Rahman S, Leapman M, Sprenkle P. Diagnostic utility of prostate health index density prior to MRI-ultrasound fusion targeted biopsy. Exploration Of Targeted Anti-tumor Therapy 2024, 5: 1168-1176. PMID: 39465014, PMCID: PMC11502073, DOI: 10.37349/etat.2024.00269.Peer-Reviewed Original ResearchProstate Health IndexMRI-ultrasound fusion targeted biopsyClinically significant prostate cancerFusion targeted biopsyPI-RADS 1Gleason grade groupMagnetic resonance imagingPhi densityPI-RADSProstate specific-antigenProstate biopsyImproved detection of clinically significant prostate cancerDetection of clinically significant prostate cancerPHI testingProstate health index densityElevated prostate-specific antigenMRI-ultrasound fusionProstate Imaging ReportingSignificant prostate cancerProstate-specific antigenSelection of patientsDetection of PCaReceiver operating characteristic curveCombination of magnetic resonance imagingMultivariate logistic regressionReply to Editorial Comment on "Association of Crowd-Sourced Assessment of Technical Skills (CSATSTM) and Outcomes of Robotic Assisted Radical Prostatectomy"
Rabil M, Leapman M, Cavallo J. Reply to Editorial Comment on "Association of Crowd-Sourced Assessment of Technical Skills (CSATSTM) and Outcomes of Robotic Assisted Radical Prostatectomy". Urology 2024 PMID: 39208938, DOI: 10.1016/j.urology.2024.08.054.Peer-Reviewed Original ResearchCost trends of metastatic renal cell carcinoma therapy: the impact of oral anticancer agents and immunotherapy
Forman R, Long J, Westvold S, Agnish K, McManus H, Leapman M, Hurwitz M, Spees L, Wheeler S, Gross C, Dinan M. Cost trends of metastatic renal cell carcinoma therapy: the impact of oral anticancer agents and immunotherapy. JNCI Cancer Spectrum 2024, 8: pkae067. PMID: 39133171, PMCID: PMC11376369, DOI: 10.1093/jncics/pkae067.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anticancer agentsOAA useAssociated with decreased adherenceRenal cell carcinomaAnticancer agentsDays of treatmentCombination therapyCell carcinomaStudy patientsInitial treatmentReal-world costsCombination groupImmunotherapyPatientsOOP costsTherapyTreatment typePercent daysPerspective of payersTreatmentClaims dataMedicare patientsAnalyzed differencesFee-for-service MedicareAssociation Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting
Leapman M, Ho J, Liu Y, Filson C, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Lin D, Spratt D, Cooperberg M, Sprenkle P, Ross A. Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting. European Urology Oncology 2024 PMID: 39098389, DOI: 10.1016/j.euo.2024.07.010.Peer-Reviewed Original ResearchDecipher genomic classifierRisk of metastasisBiochemical recurrenceRadical prostatectomyGenomic classifierDecipher testProstate cancerProstate Risk Assessment Postsurgical ScoreRisk of biochemical recurrencePatient's prostate cancerRisk of cancer recurrencePathological risk factorsProstate cancer outcomesCox proportional hazards regressionRetrospective cohort studyElectronic health record dataReal-world settingsProportional hazards regressionHealth record dataReal-world practice settingsProstate biopsyRP specimensOncological outcomesPrognostic significanceMedian ageRisk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy
Smani S, Sundaresan V, Lokeshwar S, Choksi A, Carbonella J, Brito J, Renzulli J, Sprenkle P, Leapman M. Risk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy. Exploration Of Targeted Anti-tumor Therapy 2024, 5: 981-996. PMID: 39280242, PMCID: PMC11390291, DOI: 10.37349/etat.2024.00259.Peer-Reviewed Original ResearchGleason score upgradingProstate-specific antigenRisk factorsMagnetic resonance imagingRadical prostatectomyScore upgradingAssociated with Gleason score upgradingBiopsy to radical prostatectomyHigher-risk prostate cancerPatients treated with surgeryProstate magnetic resonance imagingClinically localized diseaseGleason grade groupLow-risk diseaseRecognition of risk factorsBody mass indexGleason upgradingFinal pathologyProstate volumeProstate biopsySource of diagnostic uncertaintyBiopsy coresLocalized diseaseProstate cancerInitial managementAssociations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer
Sundaresan V, Wang R, Long J, Sprenkle P, Seibert T, Loeb S, Cooperberg M, Catalona W, Ma X, Gross C, Leapman M. Associations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer. Urology Practice 2024, 11: 965-973. PMID: 39196719, DOI: 10.1097/upj.0000000000000679.Peer-Reviewed Original ResearchLocalized prostate cancerClinically localized prostate cancerHigh-risk diseaseProstate MRIProstate cancerTreatment intensificationIntensified treatmentGenomic testingTreated patientsProstate magnetic resonance imagingEnd Results databaseLong-term patient outcomesProstate cancer prognosisRetrospective cohort studyAssociated with decreased oddsRisk stratification toolPrimary study outcomeAssociated with increased oddsMagnetic resonance imagingResults databaseStratification toolTreatment patientsCohort studyRisk strataCancer prognosisProstate-specific antigen screening for prostate cancer: Diagnostic performance, clinical thresholds, and strategies for refinement
Sundaresan V, Smani S, Rajwa P, Renzulli J, Sprenkle P, Kim I, Leapman M. Prostate-specific antigen screening for prostate cancer: Diagnostic performance, clinical thresholds, and strategies for refinement. Urologic Oncology Seminars And Original Investigations 2024 PMID: 39019723, DOI: 10.1016/j.urolonc.2024.06.003.Peer-Reviewed Original ResearchProstate specific antigenProstate cancerPSA-based prostate cancer screeningDiagnostic performanceProstate specific antigen densityProstate specific antigen velocityLow-grade prostate cancerProstate-specific antigen screeningFree prostate specific antigenTreatment of prostate cancerProstate cancer screeningClinical action thresholdsProstate volumeAntigen screeningMalignant cellsSpecific antigenCancer screeningScreening biomarkerProstateClinical roleTest characteristicsCancerClinical applicationClinical thresholdEarly detectionAssociation of Crowd-Sourced Assessment of Technical Skills (CSATSTM) and Outcomes of Robotic Assisted Radical Prostatectomy
Rabil M, Jalfon M, Heckscher D, Song Z, Li F, Martin T, Sprenkle P, Hesse D, Kim I, Leapman M, Cavallo J. Association of Crowd-Sourced Assessment of Technical Skills (CSATSTM) and Outcomes of Robotic Assisted Radical Prostatectomy. Urology 2024 PMID: 39019332, DOI: 10.1016/j.urology.2024.07.014.Peer-Reviewed Original ResearchRobotic-assisted laparoscopic prostatectomyCrowd-Sourced AssessmentGEARS scoreCrowd-sourced assessment of technical skillsRALP casesOutcomes of robot-assisted radical prostatectomyRobot-assisted radical prostatectomyExpert narrative reviewPelvic fluid collectionsPatient outcomesLikelihood of sepsisPost-operative outcomesAssociated with significant improvementsFellowship-trained urologistsAssessment of technical skillsRadical prostatectomyLaparoscopic prostatectomyAssociated with improvementsGlobal Evaluative AssessmentFluid collectionLogistic regression modelsSurgeon selectionPracticing surgeonsProstatectomySurgeonsClassification and Risk Factors for Surgical Site Infections in Radical Cystectomy: A 16-Year Analysis
Lokeshwar S, Choksi A, Smani S, Ip K, Javier-DesLoges J, Rahman S, Leapman M, Martin T, Hesse D. Classification and Risk Factors for Surgical Site Infections in Radical Cystectomy: A 16-Year Analysis. Surgical Infections 2024, 25: 580-585. PMID: 38959160, DOI: 10.1089/sur.2024.107.Peer-Reviewed Original ResearchSurgical site infectionBody mass indexRadical cystectomyCenters for Disease Control and PreventionIndependent risk factorLength of stayRisk factorsAntibiotic agentsSite infectionCenters for Disease Control and Prevention classificationRisk factors of surgical site infectionFactors associated with surgical site infectionFactors of surgical site infectionPredictive of surgical site infectionDeep incision surgical site infectionSurgical site infection predictorsOdds ratioTreatment of surgical site infectionsDeep surgical site infectionPeri-operative characteristicsPeri-operative morbidityCharlson Comorbidity IndexLogistic regression analysisSuperficial incisionalDisease Control and PreventionRisk Factors and Contemporary Management Options for Pain and Discomfort Experienced During a Prostate Biopsy
Diaz G, Webb L, Rabil M, Lokeshwar S, Choksi A, Leapman M, Sprenkle P. Risk Factors and Contemporary Management Options for Pain and Discomfort Experienced During a Prostate Biopsy. Current Urology Reports 2024, 25: 243-252. PMID: 38896314, DOI: 10.1007/s11934-024-01220-w.Peer-Reviewed Original ResearchProstate biopsyRisk factorsEffective pain management strategiesDiagnosed prostate cancerPain management strategiesIn-office proceduresModern management optionsNonadherence to treatmentContemporary management optionsEnhance patient comfortInnovative imaging modalitiesExperience of painFusion biopsyProstate volumePain intensityProstate cancerPain varyPatient ageIncreased painFollow-upIn-officeManagement optionsSurveillance adherenceBiopsyPharmacological analgesicsChanges in Facility Share of Medicaid-insured Patients With Urologic Cancers Following Implementation of the Patient Protection and Affordable Care Act
Demkowicz P, Buck M, Nie J, Marks V, Wheeler S, Dinan M, Gross C, Leapman M. Changes in Facility Share of Medicaid-insured Patients With Urologic Cancers Following Implementation of the Patient Protection and Affordable Care Act. Urology 2024, 192: 19-27. PMID: 38901803, DOI: 10.1016/j.urology.2024.06.003.Peer-Reviewed Original ResearchFacility-level changesAffordable Care ActNon-expansion statesUrological cancer patientsProportion of patientsExpansion statesBaseline proportion of patientsUrologic cancer careHigh-income zip codesCancer patientsFactors associated with changesPre-post designCancer care centerPost-ACA periodMedicaid expansion statesMultivariate logistic regressionMedicaid-insured patientsCancer careUrological cancersZip codesCare ActMedicaid patientsMedicaidLogistic regressionCare centerDevelopment of a Longitudinal Prostate Cancer Transcriptomic and Clinical Data Linkage
Leapman M, Ho J, Liu Y, Filson C, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Lin D, Spratt D, Cooperberg M, Ross A, Sprenkle P. Development of a Longitudinal Prostate Cancer Transcriptomic and Clinical Data Linkage. JAMA Network Open 2024, 7: e2417274. PMID: 38874922, PMCID: PMC11179136, DOI: 10.1001/jamanetworkopen.2024.17274.Peer-Reviewed Original ResearchConceptsElectronic health recordsCancer diagnosisClinical data linkageMedicine Clinical TermsPatterns of careProstate cancer diagnosisRadical prostatectomyCancer risk stratificationData linkageHealth recordsClinical dataMain OutcomesCancer outcomesClinical juncturesClinical careCommon Procedural Terminology codesAdministrative dataDiagnosis codesLongitudinal clinical dataCohort studyPharmacy recordsGenomic classifierProcedural Terminology codesDevelopment of prostate cancer metastasisLinkage dataMagnetic Resonance Imaging in Prostate Cancer Screening
Fazekas T, Shim S, Basile G, Baboudjian M, Kói T, Przydacz M, Abufaraj M, Ploussard G, Kasivisvanathan V, Rivas J, Gandaglia G, Szarvas T, Schoots I, van den Bergh R, Leapman M, Nyirády P, Shariat S, Rajwa P. Magnetic Resonance Imaging in Prostate Cancer Screening. JAMA Oncology 2024, 10: 745-754. PMID: 38576242, PMCID: PMC10998247, DOI: 10.1001/jamaoncol.2024.0734.Peer-Reviewed Original ResearchClinically significant PCaDetection of clinically significant PcaInternational Society of Urological PathologyClinically significant PCa detectionProstate magnetic resonance imagingMagnetic resonance imagingInsignificant PCaProstate cancerProstate cancer screeningBiopsy indicationClinically significant PCa detection rateProstate-specific antigen (PSA)-based screeningMagnetic resonance imaging pathwayOdds ratioPCa detection rateSignificant PCaPI-RADS scorePSA-based screeningResonance imagingScreening pathwayTime of magnetic resonance imagingPositive predictive valuePooled odds ratioProspective cohort studyRandomized clinical trialsOpioid prescribing trends and pain scores among adult patients with cancer in a large health system.
Baum L, Soulos P, KC M, Jeffery M, Ruddy K, Lerro C, Lee H, Graham D, Liberatore M, Rivera D, Leapman M, Jairam V, Dinan M, Gross C, Park H. Opioid prescribing trends and pain scores among adult patients with cancer in a large health system. Journal Of Clinical Oncology 2024, 42: 11059-11059. DOI: 10.1200/jco.2024.42.16_suppl.11059.Peer-Reviewed Original ResearchDocumented painHealth systemOpioid prescribingOpioid prescriptionsOpioid prescribing trendsYale New Haven Health SystemPrescribing trendsMetastatic cancerDocumented pain scoresUS health systemOpioid usePain scoresAdult patientsCalculated predicted probabilitiesFlowsheet dataRetrospective cohort studyRelated harmSolid tumor malignanciesCohort studyCancer painPrescribingContext of cancer treatmentStudy criteriaPainSurgery cohort